Rafferty Asset Management
RVNC

Rafferty Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Rafferty Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,325
Closed -$85.2K – 1203
2024
Q1 		$85.2K Sell
17,325
-11,255
-39% -$66.6K ﹤0.01% 1074
2023
Q4 		$251K Buy
28,580
+8,089
+39% +$66.3K ﹤0.01% 1043
2023
Q3 		$235K Buy
20,491
+11,478
+127% +$221K ﹤0.01% 1042
2023
Q2 		$228K Buy
9,013
+1,964
+28% +$61.2K ﹤0.01% 1068
2023
Q1 		$227K Sell
7,049
-5,531
-44% -$172K ﹤0.01% 1088
2022
Q4 		$232K Buy
+12,580
New +$288K ﹤0.01% 1056
2022
Q3 		– Sell
-12,793
Closed -$177K – 1271
2022
Q2 		$177K Buy
+12,793
New +$197K ﹤0.01% 1048
2022
Q1 		– Sell
-14,724
Closed -$240K – 1340
2021
Q4 		$240K Buy
14,724
+6,923
+89% +$115K ﹤0.01% 1189
2021
Q3 		$217K Buy
+7,801
New +$223K ﹤0.01% 1181
2021
Q1 		– Sell
-7,912
Closed -$224K – 1173
2020
Q4 		$224K Buy
+7,912
New +$205K ﹤0.01% 959

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management's RVNC Position: Q2 2024 in Review

Rafferty Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 17,325 shares — an estimated $85.2K sold.

Rafferty Asset Management first reported a position in RVNC in Q4 2020 and held it in 10 quarters. The position peaked at $251K in Q4 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

  • Rafferty Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 17,325 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $85.2K.
  • Rafferty Asset Management first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 10 quarters.
  • Rafferty Asset Management's Revance Therapeutics, Inc. position peaked at $251K in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Rafferty Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.